Detection Of Latent Pulmonary Hypertension In Genetically Susceptible Individuals.

Detection Of Latent Pulmonary Hypertension In Genetically Susceptible Individuals. - DOLPHIN-GENESIS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON53083

Enrollment

140

Registered

2017-09-06

Start date

2017-09-11

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early disease pulmonary hypertension

Interventions

None listed

Eligibility

Age

16 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of idiopathic PAH, according to ESC/ERS guidelines (ref: Galie ERJ 2015) Or Unaffected BMPR2 or other mutation carrier or other mutations associated with PAH Or Healthy relative of heritable PAH patient not carrying the disease causing mutation 2. Age >18 and

Exclusion criteria

Exclusion criteria: - Pregnant subjects - Claustrophobia - Inability to provide informed consent - In case of PAH patients: TLC

Design outcomes

Primary

Measure	Time frame
-Platelet markers (RNA profiles) -Metabolites and cytokines markers -Exosome markers -Change in mean pulmonary artery pressure (mPAP) -Change in cardiac output (CO) -Change in right atrial pressure (RAP) -Change in right ventricular ejection fraction (RVEF) (%) -Change in right ventricular end diastolic volume (RVEDV) (ml) -Change in right ventricular end systolic volume (RVESV) (ml) -Change in CPET markers: maximal work (VE), peak oxygen consumption (VO2), maximal oxygen pulse (O2-pulse), VO2 max, anaerobic threshold (AT), ventilation for a given volume of carbon dioxide production (VE/VCO2-slope) and the end-tidal CO2 tension (PET-CO2). -Change in 6 minute walking distance - Changes in pulmonary vasculature Density and abscence of pulmonary vasculature Abnormal or abberant morphology of pulmonary vasculature	—

Measure

Time frame

-Platelet markers (RNA profiles) -Metabolites and cytokines markers -Exosome markers -Change in mean pulmonary artery pressure (mPAP) -Change in cardiac output (CO) -Change in right atrial pressure (RAP) -Change in right ventricular ejection fraction (RVEF) (%) -Change in right ventricular end diastolic volume (RVEDV) (ml) -Change in right ventricular end systolic volume (RVESV) (ml) -Change in CPET markers: maximal work (VE), peak oxygen consumption (VO2), maximal oxygen pulse (O2-pulse), VO2 max, anaerobic threshold (AT), ventilation for a given volume of carbon dioxide production (VE/VCO2-slope) and the end-tidal CO2 tension (PET-CO2). -Change in 6 minute walking distance - Changes in pulmonary vasculature Density and abscence of pulmonary vasculature Abnormal or abberant morphology of pulmonary vasculature

—

Secondary

Measure	Time frame
non	—

Countries

Netherlands

Outcome results